Stock Events

Stock Events

Neovacs 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0LW0.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap22.92B
BioNTech competes in the development of novel immunotherapies, similar to Neovacs' focus on therapeutic vaccines for autoimmune diseases.
Moderna
MRNA
Mkt Cap19.51B
Moderna is involved in mRNA-based therapies, competing in the broader immunotherapy space which overlaps with Neovacs' work on autoimmune diseases.
Novavax
NVAX
Mkt Cap1.25B
Novavax operates in the development of vaccines for infectious diseases, competing indirectly with Neovacs by targeting immune system responses.
Incyte
INCY
Mkt Cap19.09B
Incyte Corporation specializes in small molecule drugs for oncology and inflammation, competing in the therapeutic area of immune modulation like Neovacs.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is known for its monoclonal antibodies and inflammatory disease treatments, directly competing with Neovacs in the immunotherapy field.
Novo Nordisk
NVO
Mkt Cap164.13B
Novo Nordisk is a leading company in diabetes and biopharmaceuticals, indirectly competing with Neovacs in the broader healthcare and biotech industry.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company focusing on antiviral drugs and other treatments, competing in the immunotherapy and biotech space relevant to Neovacs.

About

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Show more...
CEO
Mr. Hugo Brugiere
Employees
18
Country
United Kingdom
ISIN
FR0014010856

Listings

LSE
GB
0W8U.LSE
STU
DE
0LW0.STU
F
DE
0LW0.F
MU
DE
0LW0.MU

0 Comments

Share your thoughts

FAQ

What is Neovacs stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Neovacs stocks are traded under the ticker 0LW0.MU.
How many employees does Neovacs have?▼
As of April 12, 2026, the company has 18 employees.
In which sector is Neovacs located?▼
Neovacs operates in the Energy sector.
When did Neovacs complete a stock split?▼
Neovacs has not had any recent stock splits.
Where is Neovacs headquartered?▼
Neovacs is headquartered in Paris, United Kingdom.